Salta al contenuto principale
Ricerc@Sapienza
Toggle navigation
Home
Login
Home
Persone
luciana.cafforio@uniroma1.it
Luciana Cafforio
Dottorando
Struttura:
DIPARTIMENTO DI MEDICINA MOLECOLARE
E-mail:
luciana.cafforio@uniroma1.it
Pagina istituzionale corsi di laurea
Curriculum Sapienza
Pubblicazioni
Titolo
Pubblicato in
Anno
Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients
BRITISH JOURNAL OF HAEMATOLOGY
2023
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia
HAEMATOLOGICA
2022
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study
BLOOD
2021
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations
BRITISH JOURNAL OF HAEMATOLOGY
2020
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimale residual disease-oriented GIMEMA LAL1913
HAEMATOLOGICA
2020
COMPLEX KARYOTYPE IS ASSOCIATED WITH A LESS FAVORABLE OUTCOME AFTER IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (GIMEMA LLC1114).
HemaSphere 2020; 4 (S1) p 290
2020
COMPLEX KARYOTYPE AFTER IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (GIMEMA LLC1114)
Haematologica, 2020; 105(s2):s28
2020
Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
FRONTIERS IN ONCOLOGY
2019
TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER IBRUTINIB TREATMENT.
HemaSphere
2019
IBRUTINIB TREATMENT DOESN’T INDUCE TP53 CLONAL EVOLUTION IN CHRONIC LYMPHOCYTIC LEUKEMIA.
Haematologica 2019; 104(s2):1
2019
Genetic Landscape of Ultra-Stable Chronic Lymphocytic Leukemia Patients
ANNALS OF ONCOLOGY
2018
Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile
LEUKEMIA
2018
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.
BRITISH JOURNAL OF HAEMATOLOGY
2018
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics
BRITISH JOURNAL OF HAEMATOLOGY
2018
Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib
BRITISH JOURNAL OF HAEMATOLOGY
2018
TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER IMMUNOCHEMOTHERAPY AND IBRUTINIB.
Haematologica, 2018; 103 (s3): s27
2018
Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients
ONCOTARGET
2017
A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for IGHV-D-J rearrangements and BRAF-V600E mutation: lack of evidence for a common origin
BRITISH JOURNAL OF HAEMATOLOGY
2016
Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments
BRITISH JOURNAL OF HAEMATOLOGY
2016
Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia
ONCOTARGET
2016
© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma